Analyst
SVB Leerink
Analyst
Leerink Partners
Analyst
SVB Securities
Equibles does not estimate personal net worth.
Jonathan Chang is recorded as Analyst at SVB Leerink, Analyst at Leerink Partners and Analyst at SVB Securities. Jonathan Chang has spoken on 7 earnings calls and 4 other investor events across 5 companies, most recently for Aktis Oncology, Inc. on May 27, 2026. Those appearances were for Aktis Oncology, Inc. (AKTS), Kura Oncology, Inc. (KURA), Karyopharm Therapeutics Inc. (KPTI), Zai Lab Ltd (ZLAB) and NovoCure Ltd (NVCR). The companies whose calls Jonathan Chang spoke on are classified in the Healthcare sector.
“So how does the patient population in this phase zero study compare to the intended population of the phase one study in terms of tumor burden, disease stage, and prior treatment and others?”
“First, can you remind me what doses used in the 042 study and how that compares to the Siendo study and what gives you confidence in the 042 study dose?”
“First question, on these OC collaborations, evaluating the combinations with DLL3 TESOL engagers, how do these facilitate your longer-term strategy, and are there other combinations and collaborations that make sense to explore?”
“First question, how did you decide on the three dose levels being evaluated in the prostate cohorts?”
“First question, how did you decide on the three dose levels being evaluated in the prostate cohorts?”
SVB Leerink
Analyst
Source not stated
Leerink Partners
Analyst
Source not stated
SVB Securities
Analyst
Source not stated
AKTS
Biotechnology · Healthcare
KURA
Biotechnology · Healthcare
ZLAB
Biotechnology · Healthcare
NVCR
Medical Devices · Healthcare
